Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

nazartinib (EGF816)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis

Drug class:

EGFR inhibitor

Related drugs:

‹

befotertinib (1)

cetuximab (317)

osimertinib (240)

erlotinib (229)

gefitinib (183)

panitumumab (114)

lapatinib (105)

neratinib (102)

brigatinib (45)

aumolertinib (22)

amivantamab-vmjw (15)

furmonertinib (11)

mobocertinib (7)

tarloxotinib bromide (7)

nimotuzumab (5)

rociletinib (5)

tomuzotuximab (4)

necitumumab (2)

ABP 494 (cetuximab biosimilar) (1)

Compound 6a (1)

abivertinib (1)

befotertinib (1)

›

EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2	EGF816 Sensitive: C2 – Inclusion Criteria EGF816 Sensitive : C2
EGFR T790M + MET positive	Non Small Cell Lung Cancer	EGFR T790M + MET positive	Non Small Cell Lung Cancer	capmatinib + EGF816 Sensitive: C3 – Early Trials capmatinib + EGF816 Sensitive : C3	capmatinib + EGF816 Sensitive: C3 – Early Trials capmatinib + EGF816 Sensitive : C3